Louise Pettersson

TL;DR: Tumors with BFB events showed a decreased elimination rate of unstable chromosome aberrations after irradiation compared with normal cells and other tumor cells, suggesting that a combination of mitotically unstable chromosomes and an elevated tolerance to chromosomal damage leads to constant genomic reorganization in many malignancies, thereby providing a flexible genetic system for clonal evolution and progression.

TL;DR: How exome sequencing can be used for identification of leukemia‐specific mutations in samples already at diagnosis of acute myeloid leukemia is described and it is shown that targeted deep sequencing of such mutations, including single nucleotide variations, can be use for high‐sensitivity quantification of minimal residual disease in a patient‐tailored manner.

TL;DR: RQ‐PCR of the NPM1 type A mutation was more sensitive and reliable than MFC for determination of MRD, which might have clinical implications.

TL;DR: This review summarizes the methods used to determine measurable residual disease (MRD) in everyday practice with some future perspectives, and the current knowledge about the prognostic impact of MRD on outcome in acute myeloid leukemia (AML), excluding acute promyelocytic leukemia.

TL;DR: Myeloid (or granulocytic) sarcoma (MS), that is, an extramedullary tumor consisting of myeloid blastic cells, is a unique clinical presentation of any type of acute myeloids leukemia (AML), according to the World Health Organization.